Feb 14, 2024
|
The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET CORAL GABLES, Fla. , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
|
Jan 09, 2024
|
CORAL GABLES, Fla. , Jan. 09, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today reported that it has closed its underwritten public offering of shares of its common stock. The Company sold 10,000,000 shares of its common stock in the
|
Jan 05, 2024
|
CORAL GABLES, Fla. , Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, for total gross
|
Jan 04, 2024
|
CORAL GABLES, Fla. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today that it has commenced an underwritten public offering of $150,000,000 of its common stock. Catalyst also intends to grant the underwriters a 30-day
|